Germany · Delayed Price · Currency is EUR | Market Cap | 121.43B |
| Revenue (ttm) | 24.58B |
| Net Income (ttm) | 5.37B |
| Shares Out | n/a |
| EPS (ttm) | 4.27 |
| PE Ratio | 22.60 |
| Forward PE | 13.59 |
| Dividend | 2.84 (2.84%) |
| Ex-Dividend Date | Jun 13, 2025 |
| Volume | n/a |
| Average Volume | 334 |
| Open | 100.18 |
| Previous Close | 99.47 |
| Day's Range | 100.18 - 100.18 |
| 52-Week Range | 67.05 - 111.04 |
| Beta | n/a |
| RSI | 53.27 |
| Earnings Date | Aug 1, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy
As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced th...
Gilead unit to acquire cell therapy developer Interius for $350 million
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are deliver...
Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug
Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.
Gilead's Kite buying Interius BioTherapeutics for $350M
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS Health Inc. (NYSE: CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ: GILD) new HIV prevention drug Yeztugo to its commercial plans . In June, the U.S. Food and Drug Administration (FDA) ...
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.
CVS Health reportedly excludes coverage for Gilead’s new HIV drug for now
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthc...
We are positive on Gilead Sciences' base business growth: Meacham
Geoff Meacham, Managing Director at Citi Research, joins BNN Bloomberg to share his Hot Picks in biotech.
Gilead Sciences' Outperformance Means Overvalued
Our Top 10 High Growth Dividend Stocks - August 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Final Trade: BSY, GDX, MNDY, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: BSY, GDX, MNDY, GILD
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Gilead Sciences (GILD) Boosts Full-Year Outlook Amid Strong HIV Demand
Gilead Sciences (GILD) Boosts Full-Year Outlook Amid Strong HIV Demand
Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook
Gilead Sciences' stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the company's HIV franchise is not only holding firm but expanding, with its new p...
NASDAQ Index, SP500, Dow Jones Forecasts – NASDAQ Gains Ground As Gilead Sciences Soars 8%
Apple stock tested multi-month highs as rally continued.
S&P500 and Nasdaq 100: Bulls Eye Weekly Gains as Tech Stocks Drive US Indices
Apple, Gilead, and Micron drive S&P500 and Nasdaq higher; US indices hold floors as traders weigh earnings momentum against tariff uncertainty.
Stocks making the biggest moves midday: Gilead Sciences, Monster Beverage, Trade Desk, MP Materials, Sweetgreen and more
These are the stocks posting the largest moves in midday trading.
Gilead Sciences jumps after Q2 beat; Truist upgrades to Buy
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
Gilead Sciences (NASDAQ: GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per sh...
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
Gilead Sciences GILD announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.
US markets today: Wall Street inches up in choppy week as S&P 500, Nasdaq hit fresh highs
US stocks saw slight gains Friday, buoyed by strong earnings reports and easing tariff concerns, setting major indexes up for a positive week. Expedia and Gilead Sciences led the charge after exceedin...